US Patent 11840712 Engineering of DNASE enzymes for manufacturing and therapy
Patent 11840712 was granted and assigned to NEUTROLIS, INC. on December, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Infobox (+38 properties)
Article (+503 characters)
US Patent 11840712 Engineering of DNASE enzymes for manufacturing and therapy
Article
Patent abstract
The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Abdul Hakkim R.0
Tobias A. Fuchs0
Date of Patent
December 12, 2023
0Patent Application Number
172101290
Date Filed
March 23, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11840712 Engineering of DNASE enzymes for manufacturing and therapy
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
